Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
41.5 USD | +4.25% | +0.95% | -30.67% |
May. 31 | Piper Sandler Starts Apellis Pharmaceuticals With Neutral Rating, $46 Price Target | MT |
May. 24 | Apellis Pharmaceuticals, Sobi Say Pegcetacoplan Reduces Post-Transplant Kidney Diseases | MT |
Chart: Technical Analysis
Technical analysis trends
Short Term | Mid-Term | Long Term | |
---|---|---|---|
Trend | Bearish | Bearish | Neutral |
Resistance | 43.60 | 55.39 | 91.10 |
Spread/Res. | -4.82% | -25.08% | -54.45% |
Spread/Supp. | +5.73% | +5.73% | +69.18% |
Support | 39.25 | 39.25 | 24.53 |
Technical Rankings Surperformance
Short Term Timing | |
---|---|
Middle Term Timing | |
Long Term Timing | |
RSI | |
Bollinger Spread | |
Unusual Volumes |
- Stock Market
- Equities
- APLS Stock
- Charts Apellis Pharmaceuticals, Inc.